Unveiling a family of spiro-β-lactams with anti-HIV and antiplasmodial activity via phosphine-catalyzed [3+2] annulation of 6-alkylidene-penicillanates and allenoates

The molecular architecture of spirocyclic compounds has been widely explored within the medicinal chemistry field to obtain new compounds with singular three-dimensional pharmacophoric features and improved bioactivity. Herein, the synthesis of 68 new spirocyclopentene-β-lactams is described, resulting from a rational drug design and structural modulation of a highly promising lead compound BSS-730A, previously identified as having dual antimicrobial activity associated with a novel mechanism of action. Among this diverse library of new compounds, 22 were identified as active against HIV-1, with eight displaying an IC₅₀ lower than 50 nM. These eight compounds also showed nanomolar activity against HIV-2, and six of them displayed micromolar antiplasmodial activity against both the hepatic and the blood stages of infection by malaria parasites, in agreement with the lead molecule’s bioactivity profile. The spirocyclopentene-β-lactams screened also showed low cytotoxicity against TZM-bl and Huh7 human cell lines. Overall, a family of new spirocyclopentene penicillanates with potent activity against HIV and/or Plasmodium was identified. The present structure–activity relationship open avenues for further development of spirocyclopentene-β-lactams as multivalent, highly active broad spectrum antimicrobial agents.

GRAPHICAL ABSTRACT

GRAPHICAL ABSTRACT

1 Introduction

Spirocyclic compounds are characterized by having two different rings that share the same sp3 (Zheng et al., 2014) carbon, which allows a unique structural architecture (Ding et al., 2018; Xu et al., 2019). The conformational restraints and the rigidity of spirocyclic compounds mean that this class of molecules presents a reduced conformational entropy penalty, which favors putative target-ligand interactions (Zheng et al., 2014; Chupakhin et al., 2019). Thus, several spirocyclic compounds with promising and diverse bioactivities are known (Zhou et al., 2020; Alves et al., 2021a; Acosta-Quiroga et al., 2021; Boddy and Bull, 2021; Yang et al., 2022). Ledipasvir (1), (Link et al., 2014), an inhibitor of the hepatitis C virus (HCV) NS5A protein and spironolactone (2), (Gabbard et al., 2020), a potassium-sparing diuretic steroid, are examples of drugs in clinical use presenting a spirocyclic scaffold in its molecular structure (Figure 1).

FIGURE 1

FIGURE 1. Ledipasvir (1) and spironolactone (2) are the two drugs in clinical use, which contain a spirocyclic scaffold in their molecular structures. Spiro carbons are highlighted in red.

Spiro-β-lactams represent one of the most versatile and promising subclasses of spirocyclic compounds. Several spiro-β-lactams have been shown to display pharmacological properties as varied as antimicrobial, anticancer, or inhibition of cholesterol absorption activities (Dhooghe and Thi, 2019; Alves et al., 2021b). Our research team has focused a lot of its efforts on the synthesis and investigation of the reactivity of new spirocyclic lactams derived from 6-aminopenicillanic acid (6-APA). By using 6-diazo- and 6-alkylidenepenicillanates in different [3+2] dipolar cycloadditions and [3+2] annulation reaction-based synthetic strategies, an extensive and diverse library of new spiropenicillanates containing pyrazole, cyclopentene, pyrazoline, cyclopropane, and isoxazolidine rings, spiro-fused to the penicillin core’s lactam ring was generated (Santos et al., 2012; Santos and Pinho e Melo, 2013; Gomes et al., 2014; Alves et al., 2020; Alves and Pinho e Melo, 2020; Alves et al., 2021c).

Among the new chiral spiropenicillanates, spirocyclopentene-β-lactam BSS-730A (3) stood out by presenting a bioactivity profile characterized by a nanomolar activity against both HIV-1 and HIV-2 (IC_{50 HIV-1} = 0.014 μM and IC_{50 HIV-2} = 0.008 μM, respectively), and a submicromolar activity against Plasmodium berghei hepatic infection (IC₅₀ = 0.550 μM) and Plasmodium falciparum erythrocytic infection (IC₅₀ = 0.430 μM) (Figure 2) (Bártolo et al., 2021). The antiviral target and mechanism of action of BSS-730A (3) remain elusive, as the compound has no HIV antiprotease activity and acts equally well against HIV whether it is added before or at different time-points after cell infection. Moreover, no resistance mutations could be selected in HIV in the presence of BSS-730A. These results, together with the potent activity of BSS-730A against two very different microorganisms (a virus and a parasite), indicate that the molecule may act on the host cells rather than on the viruses/parasites.

FIGURE 2

FIGURE 2. Spirocyclopentene-β-lactams with potent activity against HIV and Plasmodium.

BSS-730A was the starting point for the pursuit of new bioactive spirocyclopentene-β-lactamic derivatives. In the first instance, a limited number of structural modulations were carried out, allowing a preliminary, yet relevant, qualitative structure–activity relationship (SAR) evaluation of the spirocyclopentene-β-lactams class (Alves et al., 2021c). This evaluation demonstrated that BSS-730A (3) benzhydryl ester appear to play a crucial role for the molecule bioactivity, as its removal led to an inactive derivative. On the other hand, the endowment of position 2′ of BSS-730A’s spirocyclopentene ring with small alkyl esters (i.e. methyl and ethyl ester) led to highly bioactive compounds 4 and 5 (IC_{50 HIV-1} < 0.3 μM). A similar behavior was observed when the benzoyl group of BSS-730A (3) was replaced by a methyl ester in molecule BSS-722A (6), (Bártolo et al., 2021), although its replacement by a bulkier benzyl group lead to a total loss of activity (Alves et al., 2021c). In addition, similar to lead molecule BSS-730A (3), spirocyclopentene-β-lactams 4, 5 and BSS-722A (6) also display anti-Plasmodium activity.

Overall, positions 1′ and 2′ of the cyclopentene ring in the spirocyclic core of BSS-730A (3) were suitable for structural modulation without compromising the resulting spirocyclopentene-β-lactams bioactivity. Thus, the present work constitutes a step forward in the development of a new class of broad-spectrum antimicrobials, through the synthesis of a family of new chiral spiro-β-lactams. The rational structural modulation of the highly promising lead molecule BSS-730A (3) led to the synthesis of 68 new spirocyclic penicillanates through the individual and cumulative modulation of positions 1′ and 2′ of BSS-730A’s (3) spirocyclopentene ring. Among the entire set of new molecules presented herein, 41 were evaluated for their cytotoxicity and anti-HIV-1 activity. The eight compounds most active against HIV-1 were further evaluated for their anti-HIV-2 and anti-Plasmodium activities. The results obtained show unequivocally the potential of spirocyclopentenepenicillanates development as a new generation of innovative antimicrobials with broad spectrum activity.

2 Results and discussion

2.1 Spirocyclopentene-β-lactams synthesis

The strategy for the structural modulation focused on lead molecule BSS-730A (3) comprised the endowment of two of its cyclopentene ring positions (1′ and 2′), with different functional groups. These functional groups included bulky alkyl esters, varied aryl esters, esters containing a propargyl or a cinnamyl group, and benzoyl groups. The aromatic rings were endowed with a variety of substituents, mainly at the para position. This strategy aimed both at the synthesis of new bioactive spirocyclopentenepenicillanates and the gathering of significant amount of information regarding structure–activity relationships. As illustrated in Figure 3, the general strategy comprised three rounds of structural modulation of lead spiropenicillanate BSS-730A (3), namely: 1) the first round focused on the exclusive modulation of position 2′ of the BSS-730A (3) cyclopentene ring (Structural Modulation Strategy 1); 2) the second round focused on the exclusive modulation of position 1′ of the BSS-730A (3) cyclopentene ring (Structural Modulation Strategy 2) and; 3) the third round where those structural modulations from Synthetic Strategies 1 and 2 related with higher anti-HIV-1 activities were combined, affording new compounds with structural modulations at both positions 1′ and 2’ of the BSS-730A (3) cyclopentene ring (Structural Modulation Strategy 3).

FIGURE 3

FIGURE 3. Designed structural modulation of lead molecule BSS-730A (3).

It is known that phosphine-catalyzed [3+2] annulations of allenoates with electron-deficient alkenes are an effective strategy for the synthesis of cyclopentene derivatives (Guo et al., 2018; Meng et al., 2022; Song et al., 2022). In the presence of phosphines, allenoates act as three-carbon synthons giving regioisomeric cyclopentenes upon formal [3+2] cycloaddition with asymmetrically substituted alkenes. When applied to exocyclic alkenes, this synthetic strategy provides an excellent approach for the synthesis of spirocyclic compounds. In this context, we reported for the first time the phosphine-catalyzed [3+2] cycloaddition of allenoates to 6-alkylidenepenicillanates as a route to chiral spirocyclopentene-β-lactams (Scheme 1) (Santos and Pinho e Melo, 2013; Alves et al., 2021c). The annulation reaction occurs via conjugate addition of the allenoate-derived zwitterionic species to the 6-alkylidenepenicillanates, followed by ring closure, proton transfer, and triphenylphosphine elimination reaction. The formation of α- and/or γ-regioisomers will depend on the initial attack of the dipole at C-6 of the β-lactam, which can involve either the α- or the γ-position. It is noteworthy that due to the inherent chirality of the penicillin-derived alkylidenes and its “butterfly”-like conformation, the approach of the formal 1,3-dipole to the 6-alkylidenepenicillanate is through its less hindered α-side, affording the spirocyclopentene-β-lactams in a diastereoselective manner.

SCHEME 1

Scheme 1. Phosphine-catalyzed [3+2] annulation of allenoates with 6-alkylidenepenicillanates as the 2π-component.

As previously stated, the first structural modulation strategy of BSS-730A (3) focused on the exclusive modulation of position 2′ of the lead molecule cyclopentene ring. Such purpose was achieved by varying the ester group of the monosubstituted allenoate 8 used as dipole precursor in the phosphine-catalyzed [3+2] annulations with chiral 6-alkylidenepenicillanate 7 (Table 1). The allenoates were obtained in moderate to high yields (46%–85%) through a known procedure, (Mo et al., 2014), in a process that involves a 3-step synthetic sequence, which starts with the reaction of bromoacetyl bromide with an alcohol to give an α-bromoacetate, which reacts with triphenylphosphine to afford the corresponding phosphorous ylide. The final step is the Wittig reaction of the latter with ketene, generated in situ from acetyl chloride and triethylamine, to afford the expected monosubstituted allenoates (Scheme S01). The enantiopure spirocyclic products 9 and 10 were obtained in moderate to excellent overall yields (47%–98%), and the reaction time varied from 3 to 7 h, except in the case of reaction with allenoate 8n, containing (E)-cinnamyl ester, which needed 72 h to be completed. It should also be noted that five cycloaddition reactions were carried out using a mixture of allenoate with the corresponding 2-butynoate isomer. However, this was not considered a potential problem because, as previously described in the literature (Zhang and Lu, 1995; Mbofana and Miller, 2014), the treatment of 2-butynoates with triphenylphosphine is an alternative to the use of allenoates as 1,3-dipole precursors. Concerning the cycloaddition regioselectivity, α-regioisomer 10 was always obtained as a major product.

TABLE 1

TABLE 1. Structural modulation strategy focused on the exclusive modulation of the position 2′ of the lead molecule cyclopentene ring.

A second structural modulation focused on the substituents of position 1’ cyclopentene ring was carried out (Table 2). The synthesis of these new derivatives was achieved by exploring the annulation reaction of a library of chiral alkylidenepenicillanates 11 with benzyl allenoate (8p). By carrying out the reaction in the presence of triphenylphosphine at room temperature for a few hours, the expected cycloadducts 12 and 13 were obtained in good to excellent overall yields, ranging from 66% to 97%. Unfortunately, spiro-lactams 12g/13g and 12j/13j could not be separated by flash chromatography and were obtained as an inseparable mixture of regioisomers. Curiously, this modulation on the alkylidene moiety led to a different regioselectivity, with γ-regioisomer being obtained as major product in some reactions. This trend was more pronounced in reactions, which were carried out with alkylidenes bearing strong electron-withdrawing substituents (eg., p-NO₂, p-CF₃, and 3,5-(CF₃)₂), indicating that such aromatic substituents may act as regioselectivity inducers within this specific reactivity context.

TABLE 2

TABLE 2. Structural modulation strategy focused on the exclusive modulation of the position 1′ of the lead molecule cyclopentene ring.

Next, a third modulation was carried out, aiming the conjugation of both previously described modulation approaches (Table 3). In fact, this last modulation was designed aiming the synthesis of spiro-β-lactams, which includes on positions 1′ and 2′ a combination of substituents present in the compounds synthesized via Strategies 1 and 2, with higher anti-HIV-1 activity. This allowed the simultaneous structural modulation on both positions 1′ and 2′ of the BSS-730A (3) cyclopentene ring.

TABLE 3

TABLE 3. Structural modulation strategy focused on the exclusive modulation of both positions 1′ and 2′ of the lead molecule cyclopentene ring.

The formal cycloaddition reaction of alkylidenes 11a–c with allenoates 8i, 8j, and 8n afforded the corresponding chiral spirocyclic adducts 14 and 15. Unfortunately, (E)-cinnamyl ester derivatives 14c and 15c were obtained in low overall yield. On the other hand, moderate to good overall yields were observed for p-methoxybenzyl and p-methylbenzyl derivatives. It is noteworthy that in comparison with the previously described reactions, these required longer reaction times, up to 1 week.

2.2 Biological assays

The cytotoxicity and antiviral assays against HIV-1 were performed in two rounds. The first round comprised the spiropenicillanates synthesized through rational structural modulation of positions 1′ and 2′ of BSS-730A’s cyclopentene ring (Structural Modulation Strategies 1 and 2, respectively). The results obtained in the first round guided the rational design and subsequent synthesis of new compounds, which were evaluated against HIV-1 in a second round. The compounds with more potent activity against HIV-1 (IC_{50 HIV-1} < 50 nM) were further tested against HIV-2 and Plasmodium.

Concerning the antiviral assays, the maximum percentage of inhibition (MPI) of all the compounds was determined at 25 μM. Only those showing MPI values higher than 80% were considered active and their IC₅₀ and IC₉₀ values were determined in dose-response curves.

2.2.1 Anti-HIV activity

2.2.1.1 Cytotoxicity

Before the antiviral activity screening, all spirocyclopentene-β-lactams were assayed for their in vitro cytotoxic activity (CC₅₀) in TZM-bl cells (Table 4).

TABLE 4

TABLE 4. Activity of spiro-β-lactams against HIV-1.

None of the assayed compounds showed significant toxicity, with the CC₅₀ values varying from 35.78 μM, for molecule 9i, to 215.46 μM, for molecule 9a. These results are concordant with previous reports in the literature (Alves et al., 2020; Bártolo et al., 2021; Alves et al., 2021c) and confirm the low in vitro cytotoxic profile of spirocyclopentene-β-lactams.

2.2.1.2 Anti-HIV-1 activity

The anti-HIV-1 activity of the synthesized compounds (section 2.1) will be presented individually (Table 4).

The Structural Modulation Strategy 1 afforded 15 new spirocyclopentene-β-lactamic γ-regioisomers, analogs of lead molecule BSS-730A, of which six (9i–n) showed activity against HIV-1 virus (MPI at 25 μg/ml > 80%). Three molecules (9i, 9l, and 9n) presented an MPI value of 100%. The six identified bioactive molecules displayed submicromolar IC₅₀ values against HIV-1 with spiro-β-lactam 9k being the less active with IC_{50 HIV-1} of 0.366 μM. The most active molecules of the set were spiro-β-lactams 9i and 9n, with IC_{50 HIV-1} values of 0.015 µM and 0.017 µM, respectively, values comparable to the ones presented by BSS-730A (IC_{50 HIV-1} = 0.014 µM). Furthermore, molecule 9i presented an IC_{90 HIV-1} of 0.020 µM, a value slightly lower than BSS-730A (IC_{90 HIV-1} = 0.025 µM). The antiviral activity of spiro-β-lactams 10 was not evaluated because previous studies showed that α-regioisomers derived from modulation of position 2’ of cyclopentene ring did not lead to active compounds (Santos and Pinho e Melo, 2013; Alves et al., 2021c).

Next, anti-HIV-1 activity of both γ- and α-regioisomers (12 and 13) derived from the modulation of the position 1′ of the lead molecule was accessed. Among these novel 16 derivatives, seven γ-regioisomers (12) showed interesting anti-HIV-1 activity. The most active molecule of this set was spiro-β-lactams 12a with an IC_{50 HIV-1} value of 0.019 μM. However, it was possible to identify five more molecules with IC_{50 HIV-1} values under 0.200 μM. On the other hand, no anti-HIV activity was observed for α-regioisomers 13, a behavior concordant with what has been previously observed for similar spirocyclopentenepenicillanates (Bártolo et al., 2021).

Notably, nine derivatives comprising the simultaneous structural modulation on both positions 1′ and 2′ of the BSS-730A (3) cyclopentene ring showed high inhibition values (MPI at 25 μg/ml > 90%) and low IC_{50 HIV-1} values (compounds 14a–14i). Three molecules (14a, 14c, and 14d) should be highlighted for their IC_{50 HIV-1} values under 0.020 μM. These molecules have similar or lower IC_{50 HIV-1} values when compared with our lead molecule BSS-730A [BSS-730A (IC_{50 HIV-1} = 0.014 µM), 14a (IC_{50 HIV-1} = 0.012 µM), 14c (IC_{50 HIV-1} = 0.015 µM), and 14d (IC_{50 HIV-1} = 0.015 µM)]. Moreover, molecules 14c and 14d showed lower IC_{90 HIV-1} values than BSS-730A (IC_{90 HIV-1} = 0.025 µM), 0.018 µM and 0.019 µM, respectively.

2.2.1.3 Anti-HIV-2 activity

In order to get more information about the antiviral activity of our compounds, the eight compounds with better anti-HIV-1 activity were evaluated against HIV-2 (Table 5). All compounds were also very active against HIV-2 with an inhibition of 100% of viral replication at 25 μg/ml and IC_{50 HIV-2} values, ranging from 0.011 to 0.111 μM (Table 5). Spiro-β-lactams 12a, 14a, and 9n were the most active with IC_{50 HIV-2} values of 0.011, 0.013, and 0.016 µM, respectively. It should also be highlighted that compounds 12a and 14a showed lower IC₉₀ values (0.055and 0.051 µM, respectively) against HIV-2 virus than lead molecule BSS-730A (3) (IC_{90 HIV-2} = 0.064 µM) (Bártolo et al., 2021).

TABLE 5

TABLE 5. Activity of selected spiro-β-lactams against HIV-2 (structures of the studied compounds are also included).

2.2.2 Anti-Plasmodium activity

2.2.2.1 Hepatic stage of infection

The anti-Plasmodium activity of the set of eight spirocyclopentene-β-lactams most active against HIV-1 was also determined. In a preliminary activity screen, the percentage of inhibition of hepatic infection by the rodent P. berghei parasite was determined at 1 and 10 μM (Supplementary Material, Supplementary Figure S94), for the entire set of compounds. The results showed that none of the compounds tested displayed cytotoxicity against the Huh-7 host cells. All compounds displayed potent inhibition at 10 μM, while compounds 9i, 12a, and 14a showed relatively low inhibitory activity at 1 μM (lower than 50%).

Given these encouraging results, the IC₅₀ values of six spirocyclic derivatives against P. berghei hepatic infection were determined and were found to range from 0.285 to 2.593 μM (Table 6). The lowest activity was observed for compound 14g, with an IC_{50 P. berghei} of 2.593 μM, followed by compounds 14d (IC_{50 P. berghei} = 1.997 μM) and 9n (IC_{50 P. berghei} = 1.575 μM). Of note, three of the spirocyclopentene-β-lactams screened showed submicromolar activity against the parasite’s hepatic stage of infection, with compound 9i displaying the highest activity (IC_{50 P. berghei} = 0.285 μM), two-fold more potent than the lead molecule BSS-730A (3) (IC_{50 P. berghei} = 0.550 μM).

TABLE 6

TABLE 6. Compound activity against the P. berghei hepatic stage.

2.2.2.2 Blood stage of infection

Due to its promising submicromolar activity against hepatic infection by Plasmodium, the activity of the three most promising spirocyclopentene-β-lactams (9i, 12a, and 14a) against the erythrocytic stage of P. falciparum infection was further assessed (Table 7). The three compounds showed remarkable activity, with both compounds 9i and 14a showing higher activity than BSS-730A (3) against this phase of the parasite’s life cycle, with IC_{50 P. falciparum} values of 0.336 and 0.292 μM, respectively. On the other hand, the lowest activity was observed for 12a, with an IC_{50 P. falciparum} of 0.560 μM, a value nevertheless comparable to the one presented by the lead molecule BSS-730A (3) (IC_{50 P. falciparum} = 0.430 μM).

TABLE 7

TABLE 7. Compound activity against the P. falciparum blood stage.

2.3 Structure–activity relationships

2.3.1. Anti-HIV activity

The synthesis and antiviral activity determination of 40 different BSS-730A’s new analogs allowed an extensive and qualitative analysis of structure–activity relationships of this family of spirocyclopentenepenicillanates as HIV inhibitors.

Contrary to what was observed for small alkyl ester (i.e., methyl and ethyl esters) (Alves et al., 2021c), the introduction of longer chain alkyl esters like pentyl and isopentyl esters at position 2′ of the cyclopentene ring led to molecules with no relevant anti-HIV activity. These results demonstrate that the antiviral activity of this class of spirocyclic lactams is only compatible with a limited chain length of alkyl substituents on the referred position. Aryl esters at the same position 2′ of the cyclopentene ring also proved to fully compromise the respective spirocyclopentenepenicillanates antiviral activity against HIV. Although containing a benzyl ester as substructure, benzhydryl ester at position 2′ of the cyclopentene ring also caused a total loss of anti-HIV activity, the behavior potentially imputable to the presence of an additional phenyl group leading to higher bulkiness of this substituent, which may preclude an effective interaction between the ligand and its putative biological target.

The inclusion of para substituents with electron-donating and withdrawing properties in the aromatic ring of the benzyl ester group has proven to be a successful strategy to obtain new BSS-730A derivatives with potent antiviral activity. Among the five new spirocyclopentenepenicillanates obtained through this structural modulation (9h–9l), four displayed submicromolar activity against HIV-1 (IC_{50 HIV-1} < 0.4 μM). Considering compounds 9h–l it was possible to establish a direct correlation between the magnitude of the electron effect of the para substituent (NO₂ < Cl < F < Me < MeO) (Hansch et al., 1991) and the observed anti-HIV-1 activity (9h < 9k < 9l < 9j < 9i). The presence of the highly electron-withdrawing NO₂ group led to an inactive molecule 9h, while molecule 9i containing a para-methoxy substituent, the most electron-donating substituent of the series, presents the higher activity against HIV (IC_{50 HIV-1} = 0.015 μM). This trend indicates that a benzyl ester group at cyclopentene’s 2′ position incorporating an electron-rich aromatic ring potentiates the antiviral activity of spirocyclopentenepenicillanates. Interestingly, adding conjugation to the phenyl group, going from benzyl ester derivative BSS-730A (3) to cinnamyl ester derivative 9n had also a positive impact, the latter molecule displaying nanomolar anti-HIV-1 activity.

Molecule, 9m containing a propargyl ester, should also be highlighted. Despite being one of the less active molecules resulting from Structural Modulation Strategy 1, it still presents a remarkable IC₅₀ of 0.203 μM against HIV-1. Although the terminal alkyne of propargyl ester is also an electron-rich residue, spiropenicillanate 9m lower antiviral activity may be explained by the fact that propargyl ester is unable to participate in π–π stacking interactions. However, the presence of a terminal alkyne on a yet highly active compound gives the opportunity to explore azide–alkyne click chemistry for the synthesis of conjugates (Luo et al., 2014; Kaur et al., 2021).

Through structural modulation of 6-alkylidenepenicillanates precursors, the addition of halogens to the benzoyl group of BSS-730A (3) was also performed. It was observed that compounds 12a–c bearing weak withdrawing groups (R = F, Cl, and Br) showed higher anti-HIV-1 activity than compounds 12d,e with strong withdrawing substituents (R = NO₂ and CF₃).

The para nitro aromatic substituent is the only substituent common to Structural Modulation Strategies 1 and 2 that leads to different outcomes when placed on the benzoyl or the benzyl ester group of lead molecule BSS-730A (3). While on the benzoyl group of BSS-730A (3), the nitro substituent leads to a slight decrease of the antiviral activity (molecule 12d, with submicromolar activity IC_{50 HIV-1} = 0.178 μM), the same substituent causes a total loss of antiviral activity when present on the benzyl ester group (molecule 9h). Concerning the rational design of new potentially bioactive spirocyclopentene-β-lactams, this result demonstrates that the benzoyl group at cyclopentene’s 1′position is more tolerant to the inclusion of highly electron-withdrawing substituents than the benzyl group at cyclopentene’s 2′position.

Although being 10 times less active than lead molecule BSS-730A, the fact that 1′-furoyl-substituted molecule 12i displays a remarkable submicromolar antiviral activity against HIV-1 (IC_{50 HIV-1} = 0.140 μM), which is an important outcome, as it shows that cyclopentene position 1′ can have its ketone group modulated by the incorporation of heteroaromatic rings without causing an abrupt loss of antiviral activity.

From the simultaneous structural modulation on both positions 1′ and 2′ of the BSS-730A cyclopentene ring, interesting conclusions can be drawn. It was possible to observe that the combined introduction of p-halobenzoyl groups at position 1′ together with the introduction of a p-methylbenzyl ester group at position 2′ (see compounds 14b, 14e, and 14h) did not increase the antiviral activity when compared to the outcome of the changes carried out separately (see compounds 9j, 12a, 12b, and 12c). However, combining p-halobenzoyl groups at spirocyclopentenepenicillanates’ 1′position with the introduction of a benzyl ester group at position 2′ with a strong electron donating substituent (p-methoxybenzyl ester group) led to compounds (14a, 14d, and 14g) as highly active as the lead molecule BSS-730A. The molecule 14c, containing a p-fluorobenzoyl group at position 1′ and a cinnamyl ester at position 2′, also led to very interesting results, corroborating the importance of adding conjugation to the phenyl group at position 2′ to achieve high anti-HIV activity.

Overall, the qualitative structure–activity relationship results discussed herein show that the presence of electron-rich aromatic groups in both positions 1′ and 2′ of the cyclopentene ring are associated with higher anti-HIV-1 activity. It was also possible to establish the crucial relevance of a methylene group in the ester substituent at position 2′ of the cyclopentene ring (CO₂CH₂-R) because it is a common substructure of all the bioactive spirocyclopentenepenicillanates previously (Bártolo et al., 2021; Alves et al., 2021c) and presently identified (Figure 4). This structure–activity relationship is also corroborated by the lack of antiviral activity observed for spirocyclopentene-β-lactam 9a, in which the molecular structure differs from lead molecule BSS-730A (3) exclusively by the absence of this methylene group, since molecule 9a has a phenyl ester at position 2’ while BSS-730A (3) has a benzyl ester.

FIGURE 4

FIGURE 4. Common substructure of all bioactive spirocyclopentenepenicillanates.

Nine spirocyclopentenepenicillanates were evaluated as anti-HIV-2 agents, all of them displaying nanomolar activity. Despite the extraordinary results, the presence of the p-methoxybenzyl ester group at spirocyclopentene-β-lactams’ 2′position does not have a similar impact as the one observed for the anti-HIV-1 activity, leading to a slight decrease of the anti-HIV-2 activity (compounds 9i, 14a, 14d, and 14g). Molecule 9n containing a cinnamyl ester in position 2′ displayed high anti-HIV-2 activity, with an IC_{50 HIV-2} value of 0.016 μM similar to the one shown against HIV-1.

The importance of a fluorine atom to enhance the anti-HIV-2 activity of the synthesized molecules is noteworthy. Three of the four molecules with higher anti-HIV-2 activity contain a p-fluorobenzoyl group at position 1’ [12a (IC_{50 HIV-2} = 0.011 μM), 14a (IC_{50 HIV-2} = 0.013 μM), and 14c (IC_{50 HIV-2} = 0.039 μM)]. It should be highlighted that fluorine atoms are well known bioisosteres of hydrogen atoms being the introduction of fluorine into a molecule a strategy used in the drug design to improve drug-like features (Gillis et al., 2015). This rational drug design strategy has already proven valuable on the drug development of other β-lactamic core containing drugs, namely, a series of orally active cholesterol absorption inhibitors (Rosenblum et al., 1998).

2.3.2. Anti-Plasmodium activity

The analysis of the inhibitory activity of spirocyclopentene-β-lactams against Plasmodium hepatic infection indicates that the addition of a halogen to the benzoyl aromatic ring at 1’ position causes a decrease of activity against the Plasmodium hepatic infectious stage when compared to its counterparts without aromatic substituents on such moiety. This behavior can be clearly observed in the series of compounds 9i, 14a, 14d, and 14g and in the series of compounds 3, 12a, and 12c.

Unlike what was demonstrated for both HIV-1 and HIV-2 viruses, the substitution of the benzyl ester on BSS-730A (3) by a cinnamyl ester led to a three-fold decrease of the molecule’s inhibitory activity against the parasite hepatic infectious stage. One can speculate that such result may be attributed to the increasing of the ester group chain length, which can obstruct an effective molecule-target interaction.

On the other hand, it is noteworthy that the presence of a p-MeO group on benzyl ester at position 2′ of the lead molecule’s cyclopentene ring leads to a two-fold increase on its hepatic stage antiplasmodial activity [9i (IC_{50 P. berghei} = 0.285 μM) vs. BSS-730A (3) (IC_{50 P. berghei} = 0.550 μM). However, a positive effect of the benzyl ester’s p-MeO substituent on the molecules’ activity can also be observed for the p-fluorobenzoyl derivatives 14a (IC_{50 P. berghei} = 0.750 μM) and 12a (IC_{50 P. berghei} = 0.924 μM).

The study on the antiplasmodial activity during the parasite’s blood stage of spirocyclopentene-β-lactams 9i, 12a, and 14a also allows to carry out a qualitative structure–activity analysis. Comparing to BSS-730A (3) activity (IC_{50 P. falciparum} = 0.430 μM), it was observed that the introduction of a p-MeO substituent on benzyl ester aromatic ring potentiates the molecule’s antiplasmodial activity [9i (IC_{50 P. falciparum} = 0.336 μM)], an effect that it is even more pronounced when combined with the presence of a p-F substituent on the molecule’s benzoyl group [14a (IC_{50 P. falciparum} = 0.292 μM)]. However, in the absence of the methoxy aromatic substituent, the presence of the fluorine substituent at the benzoyl group para position per se leads to a slight decrease in the molecule antiplasmodial activity [12a (IC_{50 P. falciparum} = 0.560 μM)].

Overall, the identified qualitative structure–activity relationships concerning the antimicrobial activity of the molecules developed along the present work represent an important achievement for the future rationale design of new spirocyclopentene-β-lactams with potential broad spectrum antimicrobial activity (Figure 5).

FIGURE 5

FIGURE 5. Overview of the identified structure–activity relationships.

3 Conclusion

A library of 68 new spirocyclopentene-β-lactams was synthesized through the rational drug design and structure modulation of a highly promising lead molecule BSS-730A. The strategy focused mainly on the endowment of two of the cyclopentene ring positions with different functional groups either by replacing the current substituents with bulkier alkyl esters, varied aryl esters, and esters moieties incorporating double- or triple carbon-carbon bonds (cinnamyl and propargyl esters), or by including substituents, mainly in para position, on the terminal aromatic rings of such positions.

All the screened molecules showed low cytotoxicity against TZM-bl cell line, with CC₅₀ values ranging from 35.78 to 215.46 μM. Twenty-two new spirocyclopentene-β-lactams inhibited HIV-1 replication, with IC_{50 HIV-1} values as low as 0.012 μM. The derivatives with electron-rich aromatic groups in both positions 1′ and 2′ displayed higher anti-HIV-1 activity. Among those, the eight compounds with higher anti-HIV-1 activity (IC_{50 HIV-1} < 0.050 μM) were also active against HIV-2 and Plasmodium hepatic and blood infectious stage. The most active compound against HIV-2 showed a remarkable IC_{50 HIV-2} value of 0.011 μM. It should be highlighted that among the four molecules with higher anti-HIV-2 activity three of them contain a p-fluorobenzoyl group at position 1′.

Concerning the compounds’ antiplasmodial activities, the most active spiro-β-lactam against the Plasmodium infectious hepatic stage have an IC_{50 P. berghei} value of 0.285 μM, while the spiro-β-lactam which displayed the lower IC₅₀ against the parasite blood stage showed an IC_{50 P. falciparum} value of 0.267 μM. Both the anti-HIV and antiplasmodial results presented herein represent an improvement toward the previously observed bioactivity of lead molecule BSS-730A. Given the high structural similarity between BSS-730A and its new bioactive analogs, it is estimated that the latter ones also share the lead molecule innovative antimicrobial host-based mechanism of action.

As a result of the wide pool of screened compounds, it was also possible to gather a considerable and representative amount of qualitative structure–activity information regarding the spirocyclopentene-β-lactams family of compounds, providing a strong background of structural and pharmacophoric information for further rational design and synthesis of new potentially bioactive molecules.

Altogether, the present work comprises a successful strategy of rational structure modulation and optimization of a lead molecule, allowing the identification of new twenty-two highly bioactive spirocyclopentene-β-lactams, three of which display improved antimicrobial activity against HIV and/or Plasmodium when compared to BSS-730A.

4 Experimental section

4.1 Chemistry

Thin-layer chromatography (TLC) analyses were performed using precoated silica gel plates. Flash column chromatography was performed with silica gel 60 as the stationary phase. ¹H nuclear magnetic resonance (NMR) spectra (400 MHz) and ¹³C NMR spectra (100 MHz) were recorded in CDCl₃ or hexadeuterated dimethyl sulfoxide (DMSO-d₆). Chemical shifts are expressed in parts per million (ppm) relatively to internal tetramethylsilane (TMS), and coupling constants (J) are expressed in hertz (Hz). Infrared spectra (IR) were recorded in a Fourier transform spectrometer coupled with a diamond attenuated total reflectance (ATR) sampling accessory. Elemental analyses were carried out with an Elemental Vario Micro Cube analyzer. High-resolution mass spectra (HRMS) were obtained on a TOF VG Autospect M spectrometer with electrospray ionization (ESI). Melting points (mp) were determined in open glass capillaries. Optical rotations were measured on an Optical Activity AA-5 electrical polarimeter. 6-Alkylidenepenicillanates 7 and 11 were synthesized as described in the literature (Santos and Pinho e Melo, 2013; Alves and Pinho e Melo, 2020). Full characterization of allenoates 8a–d and 8f–o (the synthesis of allenoates 8a–d (Himbert et al., 1988; Himbert et al., 1989; Conner and Brown, 2016) and 8m (Conner and Brown, 2016) has been previously described) and spiro-β-lactams 9b–o, 10b–o, 12b–j, 13b–j, 14b–i, and 15b–i can be found in the Supplementary Material.

4.2 General procedure for the synthesis of monosubstituted allenoates

The monosubstituted allenoates were obtained through a synthetic procedure, previously reported in the literature (Mo et al., 2014).

Bromoacetyl bromide (0.252 ml, 2.90 mmol) was added dropwise to a solution of alcohol (2.90 mmol) and pyridine (0.232 mL, 2.90 mmol) in DCM (10 mL) at 0°C, forming a white suspension. The suspension was stirred for 20 min at 0°C and then for an additional 30 min at 25°C, after which distilled water (15 mL) was added to the reaction mixture. The organic layer was separated, and the aqueous layer was then extracted with DCM (2 × 15 mL). The combined organic layers were washed with brine (15 mL), dried over with MgSO₄, and concentrated to give the respective α-bromoacetate as oil, which was used directly without purification for the next reaction step.

The α-bromoacetate obtained in the previous step was added dropwise to a solution of triphenylphospine (0.754 g, 2.9 mmol) in toluene (20 mL) and was left stirring overnight. The resulting precipitate was filtered, washed sequentially with toluene and hexane, and then dissolved in distilled water (20 mL). NaOH (2 M) was added to maintain the pH > 7 and the mixture was left stirring. After 30 min, DCM (20 mL) was added. The organic layer was then separated, washed with brine (15 mL), dried over with MgSO₄, and the filtrate was concentrated affording the desired phosphorus ylide, which was used directly without further purification for the next step.

The phosphorus ylide was then dissolved in anhydrous DCM (5 mL) in a two-neck round-bottled flask, and NEt₃ (0.405 mL, 2.90 mmol) was added dropwise to the solution. After stirring for 15 min, a previously prepared solution of acetyl chloride (0.212 mL, 2.90 mmol) in anhydrous DCM (5 mL) was added dropwise over 30 min. The reaction mixture was left stirring for 12 h under nitrogen. A precipitate was formed, which was filtered and discarded, and the solvent was carefully evaporated under reduced pressure. The desired allenoate was purified by flash chromatography [ethyl acetate/hexane], being obtained as oil or a low melting point solid.

4.2.1 Pentyl 2,3-butadienoate (8e)

Allenoate 8e was obtained as described in the general procedure from the corresponding alcohol (pentanol) and purified by flash chromatography [ethyl acetate/hexane (1:4)], being obtained as colorless oil (0.299 g, 1.943 mmol, 67%). NMR ¹H (400 MHz, CDCl₃) δ = 0.89 (t, J = 6.8 Hz, 3H), 1.32 (m, 4H), 1.64 (m, 2H), 4.13 (t, J = 6.8 Hz, 2H), 5.20 (d, J = 6.4 Hz, 2H), and 5.62 (t, J = 6.4 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ = 14.1, 22.4, 28.1, 28.4, 65.3, 79.3, 88.2, 166.0, and 215.9; HRMS (ESI) m/z: calculated for C₉H₁₄NaO₂ [M + Na]⁺ 177.0886; found 177.0885.

4.3 General procedure for the phosphine-catalyzed [3+2] annulation of allenoates with 6-alkylidenepenicillanates

The general procedure for the synthesis of spirocyclopentene-β-lactams through phosphine-catalyzed [3+2] annulation of allenoates with 6-alkylidenepenicillanates is described in the literature (Santos and Pinho e Melo, 2013).

To a mixture of the appropriate 6-alkylidenepenicillanate (1 equiv.) and PPh₃ (20 mol%) in toluene (2–3 mL), a solution of allene (1 equiv.) in toluene (1–2 mL) was added. The reaction mixture was stirred at room temperature under nitrogen for the time indicated in each case, being monitored through TLC. Upon completion, the solvent was removed under reduced pressure and the crude product was purified by flash chromatography.

(1′R,2′R)-Benzhydryl spiro[(2-benzoyl-3-phenoxycarbonylcyclopent-3-ene)-1′,6-penicillanate] (9a) and (1′R,2′R)-Benzhydryl spiro[(2-benzoyl-5-phenoxycarbonylcyclopent-4-ene)-1′,6-penicillanate] (10a).

Obtained from phenyl 2,3-butadienoate (8a) (33 mg, 0.21 mmol) and 6-alkylidenepenicillanate 7 (100 mg, 0.21 mmol) as described in the general procedure. The reaction mixture was stirred for 6 h. Purification of the crude product by flash chromatography [(ethyl acetate/hexane (1:4)] gave, in order of elution, 9a as a colorless solid (61 g, 0.095 mmol, 46%) and 10a as a colorless solid (71 g, 0.110 mmol, 53%).

Compound 9a: mp > 137.0°C (with decomposition); ${\left[\alpha \right]}_D^{\mathit{25}}$ = + 340 (c 0.25 in CH₂Cl₂); IR (ATR): ν = 1,772, 1,735, 1,657, and 1,490 cm ⁻¹; ¹H NMR (400 MHz, CDCl₃) δ = 1.13 (s, 3H), 1.53 (s, 3H), 3.21 (dd, J = 18.8 and 3.2 Hz, 1H), 3.64 (dt, J = 18.8 and 2.4 Hz, 1H), 4.56 (s, 1H), 5.27 (d, J = 1.2 Hz, 1H), 5.48 (s, 1H), 6.80–6.83 (m, 2H), 6.93 (s, 1H), 7.15 (m, 1H), 7.25 (br s, 1H), 7.27–7.36 (m, 12H), 7.41–7.45 (m, 2H), 7.53–7.56 (m, 1H), and 8.10–8.13 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ = 26.1, 32.6, 41.0, 53.0, 64.3, 69.1, 70.8, 71.2, 78.5, 121.5, 126.0, 127.1, 127.7, 128.5, 128.6, 128.8, 129.4, 129.5, 133.7, 135.6, 137.5, 139.2, 139.3, 147.6, 150.3, 161.4, 167.0, 176.4, and 201.2; HRMS (ESI) m/z: calculated for C₃₉H₃₃NNaO₆S [M + Na]⁺ 666.1921; found 666.1913.

Compound 10a: mp 92.5–95.0°C; ${\left[\alpha \right]}_D^{\mathit{25}}$ = + 420 (c 0.5 in CH₂Cl₂); IR (ATR): ν = 1,769, 1,735, 1,684, 1,591, and 1,490 cm ⁻¹; ¹H NMR (400 MHz, CDCl₃) δ = 1.11 (s, 3H), 1.53 (s, 3H), 2.62 (dd, J = 19.2 and 2.4 Hz, 1H), 3.29 (ddd, J = 18.8, 9.2 and 2.0 Hz, 1H), 4.54 (s, 1H), 4.62 (d, J = 8.4 Hz, 1H), 6.34 (s, 1H), 6.89 (s, 1H), 7.12–7.20 (m, 6H), 7.24–7.30 (m, 4H), 7.35–7.42 (m, 6H), 7.50–7.54 (m, 2H), 7.61–7.64 (m, 1H), and 7.97–7.99 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ = 25.8, 33.1, 36.2, 49.5, 62.8, 69.6, 71.1, 74.1, 78.3, 122.0, 126.0, 127.3, 127.6, 128.0, 128.2, 128.6, 128.6, 129.1, 129.5, 133.8, 134.0, 135.1, 139.5, 139.6, 146.3, 150.6, 161.0, 166.7, 174.2, and 198.5; HRMS (ESI) m/z: calculated for C₃₉H₃₃NNaO₆S [M + Na]⁺ 666.1921; found 666.1910.

(1′R,2′R)-benzhydryl spiro[(2-(4-fluorobenzoyl)-3-benzyloxycarbonylcyclopent-3-ene)-1′,6-penicillanate] (12a) and (1′R,2′R)-benzhydryl spiro[(2-(4-fluorobenzoyl)-5-benzyloxycarbonylcyclopent-4-ene)-1′,6-penicillanate] (13a).

Obtained from allene 8p (65 mg, 0.375 mmol) and 6-alkylidenepenicillanate 11a (188 mg, 0.375 mmol) as described in the general procedure (reaction time: 6.5 h). Purification of the crude product by flash chromatography (hexane/ethyl acetate, 4:1) gave, in order of elution, 12a as a colorless solid (119 mg, 0.175 mmol, 47%) and 13a as a colorless solid (125 mg, 0.185 mmol, 49%).

Compound 12a: mp 64.5–66.5°C; ${\left[\alpha \right]}_D^{\mathit{25}}$ = + 270 (c 0.5 in CH₂Cl₂); IR (ATR): $\stackrel{\sim }{\nu }$ = 1,063, 1,155, 1,201, 1,234, 1,330, 1,456, 1,593, 1,670, 1,718, and 1,773 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ = 1.11 (s, 3H), 1.50 (s, 3H), 3.11 (dd, J = 18.6 and 3.1 Hz, 1H), 3.53 (dt, J = 18.6 and 2.3 Hz, 1H), 4.52 (s, 1H), 4.96 (d, J = 12.2 Hz, 1H), 5.00 (d, J = 12.2 Hz, 1H), 5.10 (d, J = 1.2 Hz, 1H), 5.41 (s, 1H), 6.91 (s, 1H), 7.01 (t, J = 8.6 Hz, 2H), 7.08 (s, 1H), 7.13–7.18 (m, 2H), 7.28–7.37 (m, 13H), and 8.07 (dd, J = 5.4 and 8.9 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ = 26.1, 32.4, 40.8, 52.8, 64.3, 66.9, 69.1, 70.6, 71.1, 78.5, 115.6 (d, J = 22 Hz, 2C), 127.2, 127.7, 128.4, 128.5, 128.5, 128.6, 128.7, 128.7, 128.8, 132.1 (d, J = 10 Hz, 2C), 133.8 (d, J = 3 Hz, 1C), 135.3, 135.7, 139.2, 139.3, 146.2, 162.9, 166.1 (d, J = 256 Hz, 1C), 167.0, 176.3, and 199.6; ¹⁹F NMR (376 MHz, CDCl₃): -104.44 (s, 1F); HRMS (ESI-TOF) m/z: [M + H]⁺ calculated C₄₀H₃₅FNO₆S 676.2164; found 676.2162.

Compound 13a: mp 73.9–75.9°C; ${\left[\alpha \right]}_D^{\mathit{25}}$ = + 430 (c 0.5 in CH₂Cl₂); IR (ATR): $\stackrel{\sim }{\nu }$ = 977, 1,012, 1,151, 1,176, 1,200, 1,306, 1,374, 1,453, 1,596, 1,679, 1,718, 1,744, and 1,776 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ = 1.11 (s, 3H), 1.51 (s, 3H), 2.49 (dd, J = 18.6 and 2.5 Hz, 1H), 3.19 (ddd, J = 18.6, 9.1 and 2.0 Hz, 1H), 4.50 (d, J = 8.4 Hz, 1H), 4.54 (s, 1H), 5.21 (s, 2H), 6.27 (s, 1H), 6.91 (dd, J = 2.8 and 2.2 Hz, 1H), 6.94 (s, 1H), 7.16 (t, J = 8.6 Hz, 2H), 7.27–7.38 (m, 11H), 7.40–7.48 (m, 4H), and 7.96 (dd, J = 5.3 and 8.8 Hz, 2H);

¹³C NMR (100 MHz, CDCl₃): δ = 25.9, 32.8, 36.0, 49.4, 62.8, 66.6, 69.1, 71.0, 74.0, 78.4, 116.3 (d, J = 22 Hz, 2C), 127.5, 127.5, 128.2, 128.2, 128.4, 128.5, 128.7, 128.7, 131.2 (d, J = 9 Hz, 2C), 131.6 (d, J = 3 Hz, 1C), 134.4, 135.8, 139.6, 144.7, 162.5, 166.1 (d, J = 256 Hz, 1C), 166.7, 174.2, and 196.9; ¹⁹F NMR (376 MHz, CDCl₃): -104.18 (s, 1F); HRMS (ESI-TOF) m/z: [M + H]⁺ calculated C₄₀H₃₅FNO₆S 676.2164; found 676.2156.

(1′R,2′R)-benzhydryl spiro[(2-(4-fluorobenzoyl)-3-(4-methoxybenzyloxycarbonyl)cyclopent-3-ene)-1′,6-penicillanate] (14a) and (1′R,2′R)-benzhydryl spiro[(2-(4-fluorobenzoyl)-5-(4-methoxybenzyloxycarbonyl)cyclopent-4-ene)-1′,6-penicillanate] (15a).

Obtained from allene 8i (51 mg, 0.250 mmol) and 6-alkylidenepenicillanate 11a (125 mg, 0.250 mmol) as described in the general procedure (reaction time: 24 h). Purification of the crude product by flash chromatography (hexane/ethyl acetate, 4:1) gave, in order of elution, 14a as a colorless solid (64 mg, 0.091 mmol, 36%) and 15a as a colorless solid (69 mg, 0.097 mmol, 39%).

Compound 14a: mp 72.9–74.9°C; ${\left[\alpha \right]}_D^{\mathit{25}}$ = + 390 (c 0.5 in CH₂Cl₂); IR (ATR): $\stackrel{\sim }{\nu }$ = 1,001, 1,104, 1,156, 1,176, 1,203, 1,237, 1,330, 1,515, 1,593, 1,670, 1,710, 1,746, and 1,773 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ = 1.11 (s, 3H), 1.49 (s, 3H), 3.10 (dd, J = 18.6 and 3.1 Hz, 1H), 3.51 (dt, J = 18.5 and 2.2 Hz, 1H), 3.81 (s, 3H), 4.51 (s, 1H), 4.88 (d, J = 11.9 Hz, 1H), 4.93 (d, J = 11.9 Hz, 1H), 5.08 (d, J = 1.1 Hz, 1H), 5.40 (s, 1H), 6.80–6.82 (m, 2H), 6.91 (s, 1H), 7.01 (t, J = 8.6 Hz, 2H), 7.06–7.09 (m, 3H), 7.29–7.34 (m, 10H), and 8.06 (dd, J = 5.4 and 8.9 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃): δ = 26.1, 32.5, 40.8, 52.8, 55.4, 64.3, 66.7, 69.1, 70.7, 71.1, 78.5, 114.0, 115.5 (d, J = 21.9 Hz, 2C), 127.1, 127.3, 127.7, 128.3, 128.5, 128.7, 130.5, 132.1 (d, J = 9.4 Hz, 2C), 133.9 (d, J = 2.7 Hz, 1C), 135.8, 139.2, 139.3, 146.0, 159.9, 163.0, 166.10 (d, J = 255.4 Hz, 1C), 167.0, 176.4, and 199.6; ¹⁹F NMR (376 MHz, CDCl₃): δ = -104.56 (s, 1F); HRMS (ESI-TOF) m/z: [M + NH₄]⁺ calculated C₄₁H₄₀FN₂O₇S 723.2535; found 723.2531.

Compound 15a: mp 84.6–86.6°C; ${\left[\alpha \right]}_D^{\mathit{25}}$ = +350 (c 0.5 in CH₂Cl₂); IR (ATR): $\stackrel{\sim }{\nu }$ = 983, 1,028, 1,122, 1,152, 1,210, 1,237, 1,331, 1,457, 1,514, 1,595, 1,676, 1,712, and 1,764 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ = 1.11 (s, 3H), 1.51 (s, 3H), 2.47 (dd, J = 18.6 and 2.5 Hz, 1H), 3.17 (ddd, J = 18.5, 9.1 and 2.0 Hz, 1H), 3.80 (s, 3H), 4.49 (d, J = 8.4 Hz, 1H), 4.54 (s, 1H), 5.13 (d, J = 12.0 Hz, 1H), 5.17 (d, J = 12.0 Hz, 1H), 6.26 (s, 1H), 6.81–6.89 (m, 3H), 6.95 (s, 1H), 7.16 (t, J = 8.6 Hz, 1H), 7.27–7.37 (m, 8H), 7.40–7.50 (m, 4H), and 7.93–7.98 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ = 25.9, 32.8, 35.9, 49.4, 55.4, 62.7, 66.4, 69.1, 71.0, 74.0, 78.4, 114.1, 116.2 (d, J = 21.9 Hz, 2C), 127.5, 127.5, 128.0, 128.2, 128.3, 128.7, 128.7, 130.4, 131.2 (d, J = 9.4 Hz, 2C), 131.6 (d, J = 2.9 Hz, 1C), 134.5, 139.7, 144.5, 159.8, 162.3, 166.1 (d, J = 255.6 Hz, 1C), 166.8, 174.3, and 196.9; ¹⁹F NMR (376 MHz, CDCl₃): δ = -104.21 (s, 1F); HRMS (ESI-TOF) m/z: [M + NH₄]⁺ calculated C₄₁H₄₀FN₂O₇S 723.2535; found 723.2529.

4.4 Biological evaluation

4.4.1 Cell lines

TZM-bl cells (AIDS Research and Reference Reagent Program, National Institutes of Health, United States) were cultured in complete growth medium consisting of Dulbecco’s Minimal Essential Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml of penicillin–streptomycin (Gibco/Invitrogen, United States), 1 mM of sodium pyruvate (Gibco/Invitrogen, United States), 2 mM of L-glutamine (Gibco/Invitrogen, United States), and 1 mM of non-essential amino acids (Gibco/Invitrogen, United States). Cell cultures were maintained at 37°C in 5% CO₂.

4.5 Viruses and titration

The primary isolates of HIV-1 and HIV-2 used in this study were previously described and characterized for coreceptor usage and susceptibility to antiretroviral drugs (Borrego et al., 2011). The HIV-1 SG3.1 is a reference subtype B strain that uses the CXCR4 coreceptor. It was obtained by transfection of HEK293T cells with pSG3.1 plasmid using jetPRIME transfection reagent (Polyplus-transfection SA, Illkirch, France), according to the instructions of the manufacturer. The HIV-2 03PTHCC19 is a primary isolate that uses a CCR5 coreceptor (Borrego et al., 2011). The 50% tissue culture infectious dose (TCID₅₀) of each virus was determined in a single-round viral infectivity assay using a luciferase reporter gene assay in TZM-bl cells (Davis et al., 2009; Borrego et al., 2011) and calculated using the statistical method of Reed and Muench.

4.6 Cellular viability assays

The in vitro cytotoxicity of test compounds was evaluated in TZM-bl cells using alamarBlue cell viability reagent (Life Technologies, United States), according to the instructions of the manufacturer. The cells were cultured in the presence and absence of serial-fold dilutions of the test compounds. Each dilution of each compound was performed in triplicate wells. Medium controls (only growth medium), cell controls (cells without test compound), and cytotoxicity controls (a compound that kills cells) were employed in each assay. The cytotoxicity of each test compound was expressed by the 50% cytotoxic concentration (CC₅₀), corresponding to the concentration of compound causing a 50% decrease of cellular viability.

4.7 Anti-HIV assays

The antiviral activity of test compounds was determined in a single-round viral infectivity assay using TZM-bl reporter cells, as previously described (Davis et al., 2009; Borrego et al., 2011; Borrego et al., 2013). Briefly, TZM-bl cells were infected with 200 TCID₅₀ of HIV-1 or HIV-2 in the presence of serial-fold dilutions of the compounds in the growth medium, supplemented with diethylaminoethyl-dextran (DEAE-dextran). After 48 h of infection, luciferase expression was quantified with Pierce Firefly Luc One-Step Glow Assay Kit (ThermoFisher Scientific, Rockford, United States), according to the instructions of the manufacturer. For each compound dilution, the assay was set up in triplicate wells. Virus controls, cell controls, and inhibitors controls (drugs with a known action against each virus) were employed. Statistical analysis was performed using Prism version 5.01 for Windows (GrahPad Software, San Diego, California, United States, www.graphpad.com), with a level of significance of 5%. IC₅₀ and IC₉₀ were estimated by the sigmoidal dose-response (variable slope) equation in Prism version 5.01 for Windows (GraphPad Software, United States).

4.8 Evaluation of hepatic stage antiplasmodial activity

The inhibitory activity of test compounds on in vitro hepatic infection by P. berghei was determined by comparing the parasite load in compound- and solvent-treated P. berghei-infected Huh7 cells. Infection load was assessed by measurement of luminescence intensity in Huh7 cells infected, with a firefly luciferase-expressing P. berghei line, as previously described (Ploemen et al., 2009; António et al., 2017). Briefly, Huh7 cells were seeded in 96-well plates (1.0 × 10⁴ cells per well) the day before drug treatment and infection. The medium was replaced by another medium containing the appropriate concentration of each compound approximately 1 h prior to infection with sporozoites freshly obtained through disruption of salivary glands of infected female Anopheles stephensi mosquitoes. Sporozoite addition was followed by centrifugation at 1,800 g for 5 min. Parasite infection load was measured 48 h after infection by a bioluminescence assay (Biotium). Cell confluence, a surrogate measure of compound toxicity to Huh7 cells, was assessed by fluorescence measurements using the alamarBlue assay, according to the manufacturer’s instructions. IC₅₀ values were determined by evaluating the activity of the tested compounds at seven different concentrations ranging from 0.01 to 1, 5, or 10 μM. Specifically, non-linear regression analysis was employed to fit the normalized results of the dose-response curves, and IC₅₀ values were determined using GraphPad Prism 8.0 (GraphPad Software, La Jolla, California, United States).

4.9 Evaluation of blood stage antiplasmodial activity

Ring-stage synchronized cultures of P. falciparum strain NF54 at 2.5% hematocrit and at approximately 1% parasitemia were incubated with test compounds or dimethyl sulfoxide (DMSO, vehicle control) in 96-well plates for 48 h at 37°C in a 5% CO₂ and 5% O₂ atmosphere. Stock solutions of chloroquine (positive control) and compounds 9i, 12a, and 14a were prepared in DMSO. Working solutions were prepared from the stock solutions in complete malaria culture medium (CMCM), which consists of RPMI 1640 supplemented with 25 mM HEPES, 2.4 mM L-glutamine, 50 μg/ml gentamicin, 0.5% w/v Albumax, 11 mM glucose, 1.47 mM hypoxanthine, and 37.3 mM NaHCO₃. For each measurement, 5 μl of the culture (approximately 800,000 cells) were stained with the DNA-specific dye SYBR green I. After 20 min of incubation in the dark, the stained sample was analyzed by flow cytometry. Approximately 100,000 events were analyzed in each flow cytometry measurement. Two independent experiments were performed, and all samples were analyzed in triplicate.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Author contributions

TPM and NT contributed to conception and design of the study. AA and NA performed the synthetic work. IB, DF, and SC performed the cell biology studies. IB, MP, NT, and TPM contributed to data analysis and interpretation. AA and NA wrote the first draft of the manuscript. MP, NT, and TPM contributed to manuscript revision and editing.

Acknowledgments

The authors thank Coimbra Chemistry Centre (CQC), supported by the Portuguese Agency for Scientific Research, “Fundação para a Ciência e a Tecnologia” (FCT) through projects UIDB/00313/2020 and UIDP/00313/2020, co-funded by COMPETE2020-UE. iMed. ULisboa, Faculdade de Farmácia de Lisboa, Portugal, is supported by FCT through projects UIDB/04138/2020 and UIDP/04138/2020, cofounded by COMPETE2020-UE. MP acknowledges FCT for grant PTDC/SAU-INF/29550/2017. AA thanks FCT for fellowships SFRH/BD/128910/2017 and COVID/BD/152144/2022. IB is supported by FCT through Norma Transitória-DL57/2016/CP1376/CT0012. The authors also acknowledge the UC-NMR facility for obtaining the NMR data (www.nmrccc.uc.pt).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fchem.2022.1017250/full#supplementary-material

References

Acosta-Quiroga, K., Rojas-Peña, C., Nerio, L. S., Gutiérrez, M., and Polo-Cuadrado, E. (2021). Spirocyclic derivatives as antioxidants: A review. RSC Adv. 11, 21926–21954. doi:10.1039/d1ra01170g

PubMed Abstract | CrossRef Full Text | Google Scholar

Alves, A. J., and Pinho e Melo, T. M. V. D. (2020). Synthesis of novel chiral spiroisoxazolidine‐β‐lactams from 6‐alkylidenepenicillanates: A 1, 3‐dipolar cycloaddition approach. Eur. J. Org. Chem. 2020, 6259–6269. doi:10.1002/ejoc.202001085

CrossRef Full Text | Google Scholar

Alves, A. J. S., Alves, N. G., Caratão, C. C., Esteves, M. I. M., Fontinha, D., Bártolo, I., et al. (2020). Spiro-lactams as novel antimicrobial agents. Curr. Top. Med. Chem. 20, 140–152. doi:10.2174/1568026619666191105110049

PubMed Abstract | CrossRef Full Text | Google Scholar

Alves, A. J. S., Alves, N. G., Soares, M. I. L., and Pinho e Melo, T. M. V. D. (2021). Strategies and methodologies for the construction of spiro-γ-lactams: An update. Org. Chem. Front. 8, 3543–3593. doi:10.1039/d0qo01564d

CrossRef Full Text | Google Scholar

Alves, N. G., Alves, A. J. S., Soares, M. I. L., and Pinho e Melo, T. M. V. D. (2021). Recent advances in the synthesis of spiro-β-lactams and spiro-δ-lactams. Adv. Synth. Catal. 363, 2464–2501. doi:10.1002/adsc.202100013

CrossRef Full Text | Google Scholar

Alves, N. G., Bártolo, I., Alves, A. J. S., Fontinha, D., Francisco, D., Lopes, S. M. M., et al. (2021). Synthesis and structure-activity relationships of new chiral spiro-β-lactams highly active against HIV-1 and Plasmodium. Eur. J. Med. Chem. 219, 113439. doi:10.1016/j.ejmech.2021.113439

PubMed Abstract | CrossRef Full Text | Google Scholar

António, M., Albuquerque Inês, S., Machado, M., Pissarra, J., Meireles, P., and Prudêncio, M. (2017). Inhibition of Plasmodium liver infection by ivermectin. Antimicrob. Agents Chemother. 61, e02005–16.

PubMed Abstract | Google Scholar

Bártolo, I., Santos, B. S., Fontinha, D., Machado, M., Francisco, D., Sepodes, B., et al. (2021). Spiro-β-lactam BSS-730A displays potent activity against HIV and Plasmodium. ACS Infect. Dis. 7, 421–434. doi:10.1021/acsinfecdis.0c00768

PubMed Abstract | CrossRef Full Text | Google Scholar

Boddy, A. J., and Bull, J. A. (2021). Stereoselective synthesis and applications of spirocyclic oxindoles. Org. Chem. Front. 8, 1026–1084. doi:10.1039/d0qo01085e

CrossRef Full Text | Google Scholar

Borrego, P., Calado, R., Marcelino, J. M., Bártolo, I., Rocha, C., Cavaco-Silva, P., et al. (2011). Baseline susceptibility of primary HIV-2 to entry inhibitors. Antivir. Ther. 17, 565–570. doi:10.3851/imp1996

PubMed Abstract | CrossRef Full Text | Google Scholar

Borrego, P., Calado, R., Marcelino, J. M., Pereira, P., Quintas, A., Barroso, H., et al. (2013). An ancestral HIV-2/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity. AIDS 27, 1081–1090. doi:10.1097/qad.0b013e32835edc1d

PubMed Abstract | CrossRef Full Text | Google Scholar

Chupakhin, E., Babich, O., Prosekov, A., Asyakina, L., and Krasavin, M. (2019). Spirocyclic motifs in natural products. Molecules 24, 4165. doi:10.3390/molecules24224165

PubMed Abstract | CrossRef Full Text | Google Scholar

Conner, M. L., and Brown, M. K. (2016). Synthesis of 1, 3-substituted cyclobutanes by allenoate-alkene [2 + 2] cycloaddition. J. Org. Chem. 81, 8050–8060. doi:10.1021/acs.joc.6b01446

PubMed Abstract | CrossRef Full Text | Google Scholar

Davis, K. L., Bibollet-Ruche, F., Li, H., Decker, J. M., Kutsch, O., Morris, L., et al. (2009). Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J. Virol. 83, 1240–1259. doi:10.1128/jvi.01743-08

PubMed Abstract | CrossRef Full Text | Google Scholar

Dhooghe, M., and Thi, H. D. (2019). An update on the synthesis and reactivity of spiro-fused β-lactams. ARKIVOC 2018, 314–347. doi:10.24820/ark.5550190.p010.808

CrossRef Full Text | Google Scholar

Ding, A., Meazza, M., Guo, H., Yang, J. W., and Rios, R. (2018). New development in the enantioselective synthesis of spiro compounds. Chem. Soc. Rev. 47, 5946–5996. doi:10.1039/c6cs00825a

PubMed Abstract | CrossRef Full Text | Google Scholar

Gabbard, R. D., Hoopes, R. R., and Kemp, M. G. (2020). Spironolactone and XPB: An old drug with a new molecular target. Biomolecules 10, 756. doi:10.3390/biom10050756

PubMed Abstract | CrossRef Full Text | Google Scholar

Gillis, E. P., Eastman, K. J., Hill, M. D., Donnelly, D. J., and Meanwell, N. A. (2015). Applications of fluorine in medicinal chemistry. J. Med. Chem. 58, 8315–8359. doi:10.1021/acs.jmedchem.5b00258

PubMed Abstract | CrossRef Full Text | Google Scholar

Gomes, C. S., Pinho e Melo, T. M., Santos, B. S., Gomes, C. S. B., and Pinho e Melo, T. M. V. D. (2014). Synthesis of chiral spiropyrazoline-β-lactams and spirocyclopropyl-β-lactams from 6-alkylidenepenicillanates. Tetrahedron 70, 3812–3821. doi:10.1016/j.tet.2014.03.109

CrossRef Full Text | Google Scholar

Guo, H., Fan, Y. C., Sun, Z., Wu, Y., and Kwon, O. (2018). Phosphine organocatalysis. Chem. Rev. 118, 10049–10293. doi:10.1021/acs.chemrev.8b00081

PubMed Abstract | CrossRef Full Text | Google Scholar

Hansch, C., Leo, A., and Taft, R. W. (1991). A survey of Hammett substituent constants and resonance and field parameters. Chem. Rev. 91, 165–195. doi:10.1021/cr00002a004

CrossRef Full Text | Google Scholar

Himbert, G., Fink, D., and Diehl, K. (1988). Cycloadditionen, 12. Einfluß von Alkylgruppen am Aromaten auf die Intramolekulare Diels‐Alder‐Reaktion von allencarbonsäure‐arylestern und Allencarboxaniliden. Chem. Ber. 121, 431–441. doi:10.1002/cber.19881210308

CrossRef Full Text | Google Scholar

Himbert, G., Fink, D., Diehl, K., Rademacher, P., and Bittner, A. J. (1989). Cycloadditionen, 15. Einfluß von Substituenten in p -, m - und o -Position am Aromaten auf die intramolekulare Diels-Alder-Reaktion von Allencarbonsäure-aniliden und-phenylestern. Chem. Ber. 122, 1161–1173. doi:10.1002/cber.19891220623

CrossRef Full Text | Google Scholar

Kaur, J., Saxena, M., and Rishi, N. (2021). An overview of recent advances in biomedical applications of click chemistry. Bioconjug. Chem. 32, 1455–1471. doi:10.1021/acs.bioconjchem.1c00247

PubMed Abstract | CrossRef Full Text | Google Scholar

Link, J. O., Taylor, J. G., Xu, L., Mitchell, M., Guo, H., Liu, H., et al. (2014). Discovery of Ledipasvir (GS-5885): A potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J. Med. Chem. 57, 2033–2046. doi:10.1021/jm401499g

PubMed Abstract | CrossRef Full Text | Google Scholar

Luo, Z., Tikekar, R. V., and Nitin, N. (2014). Click chemistry approach for imaging intracellular and intratissue distribution of curcumin and its nanoscale carrier. Bioconjug. Chem. 25, 32–42. doi:10.1021/bc4002008

PubMed Abstract | CrossRef Full Text | Google Scholar

Mbofana, C. T., and Miller, S. J. (2014). Phosphine-catalyzed annulation reactions of 2-butynoate and α-keto esters: Synthesis of cyclopentene derivatives. ACS Catal. 4, 3671–3674. doi:10.1021/cs501117h

CrossRef Full Text | Google Scholar

Meng, Y., Chen, L., and Li, E.-Q. (2022). Recent advances in lewis base-catalysed chemo-diastereo- and enantiodivergent reactions of electron- deficient olefins and alkynes. Chem. Rec. 22, e202100276. doi:10.1002/tcr.202100276

PubMed Abstract | CrossRef Full Text | Google Scholar

Mo, D.-L., Wink, D. J., and Anderson, L. L. (2014). Solvent-controlled bifurcated cascade process for the selective preparation of dihydrocarbazoles or dihydropyridoindoles. Chem. Eur. J. 20, 13217–13225. doi:10.1002/chem.201403268

PubMed Abstract | CrossRef Full Text | Google Scholar

Ploemen, I. H. J., Prudêncio, M., Douradinha, B. G., Ramesar, J., Fonager, J., van Gemert, G.-J., et al. (2009). Visualisation and quantitative analysis of the rodent malaria liver stage by real time imaging. PloS One 4, e7881. doi:10.1371/journal.pone.0007881

PubMed Abstract | CrossRef Full Text | Google Scholar

Rosenblum, S. B., Huynh, T., Afonso, A., Davis, H. R., Yumibe, N., Clader, J. W., et al. (1998). Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)- hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235):  A designed, potent, orally active inhibitor of cholesterol absorption. J. Med. Chem. 41, 973–980. doi:10.1021/jm970701f

PubMed Abstract | CrossRef Full Text | Google Scholar

Santos, B., and Pinho e Melo, T. M. V. D. (2013). Synthesis of chiral spirocyclopentenyl-β-lactams through phosphane-catalyzed [3+2] annulation of allenoates with 6-alkylidenepenicillanates. Eur. J. Org. Chem. 2013, 3901–3909. doi:10.1002/ejoc.201300153

CrossRef Full Text | Google Scholar

Santos, B. S., Nunes, S. C. C., Pais, A. A. C. C., and Pinho e Melo, T. M. (2012). Chiral spiro-β-lactams from 6-diazopenicillanates. Tetrahedron 68, 3729–3737. doi:10.1016/j.tet.2012.03.022

CrossRef Full Text | Google Scholar

Song, M., Zhao, J., and Li, E.-Q. (2022). Recent advances in tertiary amine Lewis base-promoted cycloadditions of allenoates. Chin. Chem. Lett. 33, 2372–2382. doi:10.1016/j.cclet.2021.11.044

CrossRef Full Text | Google Scholar

Xu, P.-W., Yu, J.-S., Chen, C., Cao, Z.-Y., Zhou, F., and Zhou, J. (2019). Catalytic enantioselective construction of spiro quaternary carbon stereocenters. ACS Catal. 9, 1820–1882. doi:10.1021/acscatal.8b03694

CrossRef Full Text | Google Scholar

Yang, J., Wang, Y., Guan, W., Su, W., Li, G., Zhang, S., et al. (2022). Spiral molecules with antimalarial activities: A review. Eur. J. Med. Chem. 237, 114361. doi:10.1016/j.ejmech.2022.114361

PubMed Abstract | CrossRef Full Text | Google Scholar

Zhang, C., and Lu, X. (1995). Phosphine-catalyzed cycloaddition of 2, 3-butadienoates or 2-butynoates with electron-deficient olefins. A novel [3 + 2] annulation approach to cyclopentenes. J. Org. Chem. 60, 2906–2908. doi:10.1021/jo00114a048

CrossRef Full Text | Google Scholar

Zheng, Y., Tice, C. M., and Singh, S. B. (2014). The use of spirocyclic scaffolds in drug discovery. Bioorg. Med. Chem. Lett. 24, 3673–3682. doi:10.1016/j.bmcl.2014.06.081

PubMed Abstract | CrossRef Full Text | Google Scholar

Zhou, L.-M., Qu, R.-Y., and Yang, G.-F. (2020). An overview of spirooxindole as a promising scaffold for novel drug discovery. Expert Opin. Drug Discov. 15, 603–625. doi:10.1080/17460441.2020.1733526

PubMed Abstract | CrossRef Full Text | Google Scholar